cerca CERCA
Giovedì 21 Ottobre 2021
Aggiornato: 13:49
Temi caldi

Economia_E_Finanza Salute_E_Benessere Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia

comunicato stampa

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission. Under the terms of a March 2021 agreement, global contract research organization ("CRO") Inotiv, Inc. ("Inotiv") is evaluating the safety, tolerability, and toxicity of the purified recombinant SARS-CoV-2 s-protein tha...

BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study

VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Practice ("GMP") clean room facility needed for producing clinical supply of BVX-0918A, BioVaxys' ovarian cancer vaccine candidate. The design, construction and qualification of the new facility will be ded...

ora in
Prima pagina
articoli
in Evidenza